A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures

PHASE3CompletedINTERVENTIONAL
Enrollment

548

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

July 31, 2014

Study Completion Date

August 31, 2014

Conditions
EpilepsyPartial Onset Seizures
Interventions
DRUG

Lacosamide 50 mg

"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 50 mg~* Route of Administration: Oral use"

DRUG

Lacosamide 100 mg

"* Active Substance: Lacosamide~* Pharmaceutical Form: Film-coated tablet~* Concentration: 100 mg~* Route of Administration: Oral use"

DRUG

Placebo

Matching oral Placebo tablets twice daily for 16 weeks.

Trial Locations (76)

Unknown

86026, Beijing

86027, Beijing

86015, Changchun

86005, Chengdu

86032, Chengdu

86006, Chongqing

86031, Dalian

86009, Guanghzou

86007, Guangzhou

86008, Guangzhou

86013, Guangzhou

86016, Guangzhou

86014, Hangzhou

86010, Harbin

86019, Jinan

86004, Kunming

86011, Nanchang

86012, Nanchang

86028, Nanjing

86003, Qingdao

86001, Shanghai

86023, Shanghai

86025, Shanghai

86021, Shenyang

86020, Shijiazhuang

86022, Suzhou

86002, Taiyuan

86018, Wuhan

86024, Wuhan

86017, Xi'an

86029, Xiamen

81056, Asaka

81030, Fujisawa

81013, Fukuoka

81054, Fukuoka

81057, Hachinohe

81008, Hakodate

81027, Hamamatsu

81004, Himeji

81018, Hiroshima

81019, Iwanuma

81012, Kagoshima

81033, Kitakyushu

81017, Kobe

81024, Kodaira

81010, Kokubunji

81032, Kōshi

81014, Kurume

81047, Kyoto

81035, Nagakute

81028, Nagoya

81029, Nagoya

81040, Nara

81007, Neyagawa

81002, Niigata

81046, Ohmura

81005, Okayama

81011, Saitama

81042, Sakai

81025, Sapporo

81048, Sapporo

81053, Sapporo

81009, Sayama

81020, Sendai

81031, Sendai

81021, Shimotsuke

81022, Shimotsuke

81026, Shinjuku

81003, Shizuoka

81023, Suita

81051, Suita

81052, Suita

81016, Takatsuki

81006, Toyonaka

81050, Ube

81001, Yamagata

All Listed Sponsors
collaborator

UCB Japan Co. Ltd.

INDUSTRY

lead

UCB Pharma SA

INDUSTRY

NCT01710657 - A Trial to Evaluate the Efficacy and Safety of Adjunctive Therapy With Lacosamide in Adults With Partial-Onset Seizures | Biotech Hunter | Biotech Hunter